Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
19.73
-0.58 (-2.86%)
At close: Oct 23, 2026, 4:00 PM EDT
19.62
-0.11 (-0.54%)
After-hours: Oct 23, 2026, 7:30 PM EDT
Acadia Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Acadia Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $30.53. The average 1-year stock price forecast is 54.74% higher than the current stock price, while the lowest is $16 (-18.91%) and the highest is $37 (+87.53%).
Price Target: $30.53 (+54.74%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Acadia Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 11 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 21 | 21 | 21 | 21 | 20 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Buy Reiterates $35 | Buy | Reiterates | $35 | +77.39% | Oct 19, 2026 |
| UBS | UBS | Hold Downgrades $49 → $23 | Hold | Downgrades | $49 → $23 | +16.57% | Oct 13, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $34 | Buy | Maintains | $34 | +72.33% | Oct 12, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $31 | Buy | Reiterates | $31 | +57.12% | Oct 9, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $37 → $36 | Buy | Maintains | $37 → $36 | +82.46% | Oct 8, 2026 |
Financial Forecast
Revenue This Year
1.27B
from 1.07B
Increased by 18.71%
Revenue Next Year
1.43B
from 1.27B
Increased by 12.44%
EPS This Year
0.60
from 0.83
Decreased by -28.29%
EPS Next Year
0.92
from 0.60
Increased by 54.73%
EPS and Forward PE are based on non-GAAP adjusted numbers.